GACETA MÉDICA DE MÉXICO

Gac Med Mex. 2015;151:306-14

ORIGINAL ARTICLE

Efficacy of racecadotril vs. smectite, probiotics or zinc as an integral part of treatment of acute diarrhea in children under five years: A meta-analysis of multiple treatments

Pedro Gutiérrez-Castrellón¹*, Anna Alejandra Ortíz-Hernández², Beatriz Llamosas-Gallardo², Mario A. Acosta-Bastidas², Carlos Jiménez-Gutiérrez³, Luisa Diaz-García⁴, Anahí Anzo-Osorio⁴, Juliana Estevez-Jiménez², Irma Jiménez-Escobar⁵ and Rosa Patricia Vidal-Vázquez⁶

¹Health Translational Research Unit, Hospital General Dr. Manuel Gea González, México, D.F., México; ²Emergency Deartment, Instituto Nacional de Pediatría, México, D.F., México; ³Evidence Analysis Unit and Cochrane Group, Hospital General Dr. Manuel Gea González, México, D.F., México; ⁴Department of Research Methodology, Instituto Nacional de Pediatría, México, D.F., México; ⁵Medical Direction, Hospital General Dr. Manuel Gea González, México, Mexico, ⁶Department of Strategic Projects, Hospital General Dr. Manuel Gea González, México, D.F., México; ⁶Department of Strategic Projects, Hospital General Dr. Manuel Gea González, México, D.F., México, Mexico, Me

PERMANYER

Abstract

Rationale: Despite major advances in treatment, acute diarrhea continues to be a public health problem in children under five years. There is no systematic approach to treatment and most evidence is assembled comparing active treatment vs. placebo. **Objective:** Systematic review of evidence on efficacy of adjuvants for treatment of acute diarrhea through a network meta-analysis. **Methods:** A systematic search of multiple databases searching clinical trials related to the use of racecadotril, smectite, Lactobacillus GG, Lactobacillus reuteri, Saccharomyces boulardii and zinc as adjuvants in acute diarrhea was done. The primary endpoint was duration of diarrhea. Information is displayed through network meta-analysis. The superiority of each coadjutant was analyzed by Sucra approach. **Results:** Network meta-analysis showed racecadotril was better when compared with placebo and other adjuvants. Sucra analysis showed racecadotril as the first option followed by smectite and Lactobacillus reuteri. Interpretation: Considering a strategic decision making approach, network meta-analysis allows us to establish the therapeutic superiority of racecadotril as an adjunct for the comprehensive management of acute diarrhea in children aged less than five years. (Gac Med Mex. 2015;151:306-14)

Corresponding author: Pedro Gutiérrez Castrellón, pedro.gutierrez@ideas-salud.mx

KEY WORDS: Multiple Meta-analysis. Diarrhea treatment. Children.

ntroduction

Correspondence: *Pedro Gutiérrez-Castellón

Calzada de Tlalpan, 4800

Despite major advances over the past few decades in the use of efficient oral hydration regimens, acute diarrheal disease in children younger than 5 years

Col. Sección XVI, Del. Tlalpan, C.P. 14080, México, D.F., México

Unidad de Investigación Translacional en Salud Subdirección de Investigación Biomédica Hospital de General Dr. Manuel Gea González

E-mail: pedro.gutiérrez@ideas-salud.mx

continues to represent a relevant health problem that generates significant morbidity and an important burden imposed on society¹. Currently, it is considered to be responsible for 10% of all deaths in children < 5 years of age, which in absolute numbers represents around 800,000 deaths every year and 240,000

Date of reception: 24-03-2014 Date of acceptance: 03-06-2014 visits to the emergency department/country/year^{2,3}. It generates hospitalization rates of 1 in every 25 children < 5 years of age with acute diarrhea⁴ and produces USD 11,465,541 in direct costs for each 100,000 sick children; it is estimated to produce over 2 trillion dollar expenses for outpatient or hospital management^{5,6}.

Despite the ubiquity of the disease, and the amount and diversity of publications on the subject, there are significant variations in the world on the type of treatments established for this type of children⁷. Recently, a survey on prescription patterns by emergency pediatricians in the USA⁸ and an analysis of practice patterns in Canada⁹ documented significant variations in therapeutic approaches, many of them due to inconsistent implementation of existing clinical practice guidelines (CPG) or medical directives. This way, only 28% of emergency physicians were identified to efficiently manage a CPG/care pathway and only in 38% of the cases were there written and validated directives on oral hydration standardized management¹⁰.

When recently published or about to be published CPGs for the treatment of acute diarrheal disease are analyzed, we find that, although most of them are consistent with regard to the recommendation of reduced-osmolarity oral rehydration solutions as the cornerstone of treatment and recommendations to a larger or lesser extent of other coadjuvant agents such as racecadotril, smectite, probiotics and zinc, most recommendations originate in separately-analyzed clinical trials or systematic reviews with meta-analyses assembled in a traditional manner, which practically entirely include direct comparisons of any of the above mentioned coadjuvants, with no indirect comparison analyses of these with each other having been conducted up to this moment¹¹⁻¹⁶.

In view of all of this, we decided to conduct a systematic review of evidence published until February 2014 and to present it as a meta-analysis of multiple treatments, with the purpose of making an integration of data through direct and indirect comparisons and, this way, being able to comprehensively summarize the information, trying to offer guidelines for cost-efficient decision making in this field.

Methods

A systematized and thorough search was carried out in Medline, Embase, Cumulative Index to Nursing and Allied Health (CINAHL), PsychINFO, the Cochrane Central Register of Controlled Trials, Lilacs, Artemisa and the clinical trial databases of the main international regulatory agencies in order to identify relevant studies published since 1960 and up to February 28, 2014. Previously validated sensitive and specific search algorithms were used¹⁷ for identification of all clinical trials involving the use of racecadotril, smectite, L. GG, L. reuteri, S. bolulardii and zinc. All relevant authors were contacted, as well as manufacturers of the products under analysis in order to identify non-published data. Only double-blind, randomized, controlled trials (RCTs) comparing any of the aforementioned medications with placebo for in-hospital or outpatient treatment of acute diarrheal disease in children younger than 5 years were included. The primary outcome analyzed was duration of diarrhea (hours) after the treatment under evaluation was started, whereas secondary outcome measures were fecal output at 48-72 h of study and frequency of adverse events.

Assessment of the studies was made pair-wise, in a blinded and independent manner using the risk assessment method described by the Cochrane Collaboration^{18,19}. Any disagreement on the evaluation of articles was solved using the Delphi methodology²⁰, which was always coordinated by the investigator responsible of the publication. According to the Cochrane Collaboration recommendations on systematic reviews preparation, a structured format was used to capture information in order to ensure the highest possible consistency. Obtained data were: general characteristics of the publication (first author, publication year, jornal of publication, setting where the investigation was conducted and type of funding), characteristics of participants (age, gender, underlying diseases, duration and severity of diarrheal symptoms before entering the study), received treatments (type of administered rehydration solutions, use of medications, dosing, duration of treatments) and analyzed outcomes.

Statistically, the information was analyzed using the multiple treatments meta-analysis approach. Considering that the common denominator of all studies was the use of placebo, we decided to use this maneuver as the central point for direct comparisons. Dichotomous outcomes were analyzed with the total number of randomly assigned participants as the denominator. For the secondary efficacy analysis, measured as binary outcomes, outcomes were imputed for participants' missing data, assuming that all patients with missing data were non-responders. When data on withdrawals was reported, these were included in the analysis. Descriptive statistics on population characteristics and its results was reported for each potentially eligible

study, describing the type of comparison and the most important clinical and methodological variables. For each paired comparison (direct or indirect), in the case of continuous numerical variables, Hedges' adjusted standardized mean difference (SMD) was calculated, whereas for dichotomous outcomes, their respective odds ratio was calculated, in both cases with the corresponding 95% confidence interval (95% Cl). Initially, we prepared a pair-wise meta-analysis of all published studies. We used a random effect model considering that different studies estimated different treatment effects. Simultaneously, we calculated the I2-statistic and its corresponding p-value to objectively assess the degree of heterogeneity.

Subsequently, we assembled a multiple-treatment meta-analysis using a random effects model with a Bayesian approach^{21,22} and summarized the results using the effect sizes and their credibility intervals. We used an adjustment model as described by Salanti, et al.²³.

Additionally, we calculated the superiority likelihood of each anti-diarrheal medication by means of a SU-CRA analysis and presented it with a relative arrangement graph²⁴.

To estimate inconsistency (discordance between direct and indirect evidence with a 95% CI without including zero), we calculated the difference between direct and indirect estimates, using as reference only constructed indicators that would have included the use of placebo as common maneuver²⁵.

Additionally, we adjusted the model with and without consistency assumptions and compared both models in terms of goodness of fit and parsimony²⁶.

In case of significant inconsistence, we examined the distribution of clinical variables that could be potential source of heterogeneity or inconsistency within each group of specific comparisons. All analysis and graphical representations were performed in STATA 12 for Mac.

Results

Of a total of 128 potential trials to be included, 50 RCT were finally included²⁷⁻⁷⁷ in the multiple-treatment meta-analysis, and the nine treatment modalities were analyzed using them: racecadotril, smectite, *L*. GG at doses > 10^{10} colony-forming units (CFU), *L*. GG at doses $\leq 10^{10}$ CFU, *L*. reuteri, *S*. boulardii, zinc in > 6-month, zinc in \leq 6-month children and placebo. All included studies compared two groups and had the comparison with placebo in common. When total included patients were added



Figure 1. Direct and indirect comparisons of coadjuvant agents in the treatment of acute diarrhea in children younger than 5 years.

up, we identified that 5,391 chidren were assigned to placebo and 5,324 to any of the other medications. Average duration of the studies was 4.5 ± 1.3 days and average sample size was 90 ± 89 patients per study. With regard to clinical characteristics, the majority of studies included children with moderate to severe diarrhea; 54% of the studies were conducted in oral rehydration rooms, where children were invited to remain hospitalized in order to measure the fecal output rate, whereas the rest of the studies were conducted with outpatients. Except for the direct comparisons of each medication with placebo, the 56 comparisons between medications other than placebo were indirect (Fig 1).

When the impact of medications and placebo on diarrhea duration was analyzed by means of direct comparisons, the meta-analysis demonstrated significant efficacy for practically all medications except for *L*. GG at doses < 10^{10} CFU and zinc in children younger than 6 months (Fig. 2, Table 1).

The multiple-treatment meta-analysis where both direct and indirect comparisons were assessed, identified superiority for racecadotril over the rest of coadjuvant agents, followed by smectite, and there was an apparent therapeutic equivalence between the different types of analyzed prebiotics when they were compared to each other; similarly, we identified therapeutic equivalence between the different types of prebiotics when they were compared with zinc administration in children older than 6 months (Fig. 3).

In order to demonstrate the consistency of both direct and indirect comparisons, a funnel plot modeling was used, and a very similar pattern of behavior was

$ \begin{aligned} \hline 2n & c = n contis \\ productions \\ pro$	Author, Year, Medication	SMD (95% CI)	Weight (
$ \begin{array}{c} \text{Decrement, reso} \\ \text$	Zinc > 6 months		0.00
Fajoli. 2006 0.04 (de -0.58 a -0.62) 2.09 Bahl, 2002 0.81 (de -0.58 a -0.62) 2.09 Partuge, 1990 -0.82 (de -0.58 a -0.62) 2.21 $z = 132; p = 0.05; l2 = 76.8%; p = 0.001$ -0.20 (de -0.41 a -0.62) 2.01 Corear, 2002 -0.18 (de -0.58 a -0.62) 2.21 Amecadorii -0.20 (de -0.41 a -0.62) 2.21 Corear, 2002 -0.83 (de -0.33 a -0.03) 2.21 Swiths, 2006 -0.23 (de -0.41 a -0.62) 2.21 Castarar-Undo, 2000 -2.42 (de -3.08 a -0.71) 2.16 Satarar-Undo, 2000 -3.28 (de -3.33 a -1.52) 10.24 Castarar-Undo, 2000 -3.28 (de -3.33 a -1.52) 10.24 Castarar-Undo, 2000 -0.44 (de -0.80 a -0.08) 2.14 Ganadami, 2000 -0.44 (de -1.52 a -0.80) 2.14 Ganadami, 2000 -0.44 (de -1.52 a -0.80) 2.16 Lasinski, 2002 -1.10 (de -1.52 a -0.80) 2.16 Lasinski, 2002 -1.42 (de -0.80 a -0.31) 2.17 Thew, 2008 -0.41 (de -1.52 a -0.30) 2.17 Carea, 2011 -0.23 (de -0.51 a -0.41) 2.17 Carea, 2011 <t< td=""><td>Patel 2009</td><td>-0.20 (de -0.76 a 0.35) 0.06 (de -0.11 a 0.24)</td><td>2.03</td></t<>	Patel 2009	-0.20 (de -0.76 a 0.35) 0.06 (de -0.11 a 0.24)	2.03
Duffa 2011 Duffa 2011 Duffa 2011 Duffa 2011 Duffa 2015 Duffa	Fajolu, 2008	-0.04 (de -0.55 a 0.47)	2.06
$ \begin{array}{c} \text{Pairl}, \text{Aux}, \text{res} \\ \text{Total } (\mu = -0.36 \mu \text{C}) & (\mu = -0.38 \mu \text{C}) & ($	Dutta, 2011 -	-1.08 (de -1.54 a -0.62)	2.09
$ z = 152; p = 0.05; 12 = 76.8\%; p = 0.001 $ $ z = 6.20; (dz = -0.41 \pm 0.00) $ $ 12.82 $ $ Racecadoril Coycara, 2002 Satiszar-Lindo, 2000 Satiszar-Lindo,$	Farugue, 1999	-0.12 (de -0.26 a 0.02) -0.18 (de -0.33 a -0.03)	2.22
Racecadril -1.04 (de -1.36 a - 0.71) 2:16 Savitha. 2006 -2.42 (de -3.03 a - 0.73) 195 Gezard, 2001 -3.32 (de -3.73 a - 2.82) 2.09 Salizar-Lindo, 2000 -3.33 (de -5.13 a - 1.52) 102 Shorikova, 1997 -4.4 (de -0.08) 2.14 Shorikova, 1997 -0.44 (de -0.83 a -0.71) 2.20 Gaunadiain, 2000 -4.4 (de -0.80 a -0.88) 2.14 Basu, 2009 -1.33 (de -1.78 a -0.48) 198 Costa-Hiberio, 2003 -1.13 (de -1.78 a -0.48) 2.16 Basu, 2007 -0.32 (de -0.38 a -0.13) 2.14 Subclardii -1.24 (de -1.08 a -0.51) 2.14 Variabili, 2005 -1.13 (de -1.78 a -0.48) 2.16 Correa, 2011 -0.23 (de -0.23 a -0.13) 2.17 Jastewick, 2002 -0.79 (de -1.08 a -0.51) 2.11 Variabili, 1997 -0.33 (de -1.78 -0.48) 2.14 Variabili, 2006 -0.79 (de -1.08 a -0.51) 2.17 Variabili, 2007 -0.32 (de -0.37 a -0.13) 2.17 Variabili, 1997 -0.33 (de -1.67 a -0.26) 2.14 Bilo, 2007 -0.32 (de -1.78 -0.40)	z = 1.92; p = 0.05; l2 = 76.8%; p = 0.001	-0.20 (de -0.41 a 0.00)	12.82
Savitha, 2006 Cezard, 2001 Savitarez-Castral-Lindo, 2000 Galazar-Lindo, 2000 L GG > 10° CFU Costa-Hibein, 2007 L GG > 10° CFU Costa-Hibein, 2007 Soluzir-Kala, 1994 Costa-Hibein, 2007 Costa-Hibein, 2007 L GG > 10° CFU Costa-Hibein, 2007 Soluzir-Kala, 1994 Costa-Hibein, 2007 L GG > 10° CFU Costa-Hibein, 2007 Soluzir-Kala, 1994 Costa-Hibein, 2007 L GG > 10° CFU Costa-Hibein, 2007 L GG < 10° CFU Costa (de -10° a -0.5) C GG (de -13° a -0.7) L GG (de -13°	Racecadotril Cojocaru, 2002	-1.04 (de -1.36 a -0.71)	2.16
Cazard, 2001	Savitha, 2006	-2.42 (de -3.09 a -1.75)	1.95
$ \begin{array}{c} \text{catality accurate line in 2008} &&& &&&&&&&$	Cezard, 2001	-3.28 (de -3.73 a -2.82)	2.09
$ \begin{array}{c} z = 3.61; p = 0.0001; l2 = 98.5\%; p = 0.0001 \\ L & GG > 10^{\circ} CFU \\ Guandalini, 2000 \\ Basu, 2009 \\ Basu, 2009 \\ Costar-Hibeiro, 2003 \\ Costar-Hibeiro, 2005 \\ Hive, 2005 \\ Correa, 2011 \\ Correa, 2012 \\ Correa, 2011 \\ Correa, 2012 \\ Correa, 2011 \\ Correa, 2012 \\ Correa, 2011 \\ Correa, 2012 \\ Corre$	Gutiérrez-Castrellon 1, 2008	-6.65 (de -7.27 a -6.04)	1.99
$ L \ G3 - 10^{10} \ CFU \ Guardialini, 2000 \ Basu, 2009 \ -1.72 (de -1.92 a - 0.48) (de -0.66 a - 0.29) 2.14 \ -0.43 (de -0.66 a - 0.29) 2.19 \ Basu, 2009 \ -1.72 (de -1.92 a - 0.48) (-1.92 a - 0.90) (-1.43 (de -1.92 a - 0.90) (-2.16) (-1.92 a - 0.51) (-2.17) (-2.16) (-1.92 a - 0.51) (-2.17) (-2.16) (-1.92 a - 0.51) (-2.17) (-2.16) (-2.16) (-2.16) (-2.17) (-2.16) (-2.$	z = 3.61; p = 0.0001; l2 = 98.5%; p = 0.0001	–3.33 (de –5.13 a –1.52)	10.24
Guandalni, 2000 -0.43 ($de - 0.68 - 0.20$) 2.19 Jasu, 2009 -0.43 ($de - 0.68 - 0.20$) 2.10 Joslaur, Kalla, 1994 -0.43 ($de - 1.68 - 0.58$) 2.20 Costa-Ribeiro, 2003 -0.43 ($de - 1.68 - 0.58$) 2.10 Jasinski, 2002 -1.13 ($de - 1.68 - 0.58$) 2.10 Ritchie, 2010 -2.32 ($de - 0.58 - 0.20$) 2.16 Jasinski, 2002 -0.43 ($de - 1.68 - 0.58$) 2.10 Nucgol, 2005 -0.79 ($de - 1.08 - 0.51$) 2.17 Vilazor -0.33 ($de - 0.51 - 0.20$) 2.18 Correa, 2011 -0.43 ($de - 1.08 - 0.51$) 2.17 Dajdic, 2011 -0.43 ($de - 1.08 - 0.51$) 2.11 Vilazor -0.35 ($de - 0.79 - 0.12$ 2.11 Vilazor -0.33 ($de - 0.54 - 0.61$) 2.11 -0.43 ($de - 1.08 - 0.51$) 2.17 Vilazor -0.35 ($de - 0.79 - 0.20$ 2.11 Vilazor -0.35 ($de - 0.51 - 0.20$) 2.11 Vilazor -0.43 ($de - 1.08 - 0.51$) 2.11 Vilazor -0.43 ($de - 1.31 - 0.01$) 2.14 Vilazor -0.43 ($de - 1.32 - 0.02$) 2.14	L GG > 10 ¹⁰ CFU Shornikova, 1997	-0.44 (de -0.80 a -0.08)	2.14
$\begin{array}{c} \text{Hasu, 2009} \\ \text{Costa-Ribeiro, 2003} \\ \text{Bern Canar, 2007} \\ \text{Jasinski, 2002} \\ \text{Bern Canar, 2007} \\ \text{Jasinski, 2002} \\ \text{Intchie, 2010} \\ \text{Jasinski, 2002} \\ \text{Soular/Kails, 2002} \\ \text{Soular/Kails, 2002} \\ \text{Soular/Kails, 2005} \\ \text{Soular/Kails, 2005} \\ \text{Soular/Kails, 2005} \\ \text{Soular/Kails, 2005} \\ \text{Costa-Ribeiro, 2005} \\ \text{Correa, 2011} \\ \text{Datys, 2002} \\ \text{Correa, 2011} \\ \text{Costa-Ribeiro, 2006} \\ \text{Costa-Ribeiro, 2006} \\ \text{Costa-Ribeiro, 2006} \\ \text{Costa-Ribeiro, 2007} \\ \text{Costa-Ribeiro, 2006} \\ \text{Costa-Ribeiro, 2006} \\ \text{Costa-Ribeiro, 2007} \\ \text{Costa-Ribeiro, 2007} \\ \text{Costa-Ribeiro, 2006} \\ \text{Costa-Ribeiro, 2007} \\ \text{Costa-Ribeiro, 2006} \\ \text{Costa-Ribeiro, 2007} \\ \text{Costa-Ribeiro, 2009} \\$	Guandalini, 2000	-0.43 (de -0.66 a -0.20)	2.19
$ \begin{array}{c} \text{isotentriana, 1997} \\ \text{isotentriana, 2007} \\ \text{Jarinsk, 2002} \\ \text{Riche, 2010} \\ \text{Z} = 3.32, p = 0.001; 2 = 94.2\%; p = 0.0001 \\ \text{Z} = 3.32, p = 0.001; 2 = 94.2\%; p = 0.0001 \\ \text{Z} = 3.32, p = 0.001; 2 = 94.2\%; p = 0.0001 \\ \text{Z} = 3.32, p = 0.001; 2 = 94.2\%; p = 0.0001 \\ \text{Z} = 3.32, p = 0.001; 2 = 94.2\%; p = 0.0001 \\ \text{Z} = 3.32, p = 0.001; 2 = 97.8\%; p = 0.0001 \\ \text{Z} = 3.32, p = 0.001; 2 = 97.8\%; p = 0.001 \\ \text{Z} = 5.7; p = 0.0001; 2 = 97.8\%; p = 0.0001 \\ \text{Z} = 6.34; p = 0.001; 2 = 97.8\%; p = 0.0001 \\ \text{Z} = 6.34; p = 0.001; 2 = 97.8\%; p = 0.001 \\ \text{Z} = 6.34; p = 0.001; 2 = 97.8\%; p = 0.001 \\ \text{Z} = 6.34; p = 0.001; 2 = 97.8\%; p = 0.001 \\ \text{Z} = 6.34; p = 0.0001; 2 = 97.8\%; p = 0.001 \\ \text{Z} = 6.34; p = 0.0001; 2 = 97.8\%; p = 0.0001 \\ \text{Z} = 0.68; (-117, 4 = 0.48; 0 , -17); 169 \\ \text{Z} = 0.68; (-117, 4 = 0.48; 0 , -17); 169 \\ \text{Z} = 0.68; (-117, 4 = 0.48; 0 , -17); 169 \\ \text{Z} = 0.68; (-117, 4 = 0.48; 0 , -17); 169 \\ \text{Z} = 0.68; (-113, 4 = 0.77; 0 , -18); 0.000 \\ \text{Z} = 0.68; (-113, 4 = 0.77; 0 , -18);$	Basu, 2009	-1.72 (de -1.92 a -1.51)	2.20
Berni Canari, 2007 Hitchie, 2010 z = 3.32; p = 0.001; l2 = 94.2%; p = 0.0001 Solution Hitchie, 2010 z = 3.32; p = 0.001; l2 = 94.2%; p = 0.0001 Solution Hitchie, 2010 z = 3.32; p = 0.001; l2 = 94.2%; p = 0.0001 Solution Hitchie, 2010 z = 3.32; p = 0.001; l2 = 94.2%; p = 0.0001 Solution Hitchie, 2010 z = 3.32; p = 0.0001; l2 = 94.2%; p = 0.0001 Hitchie, 2010 -0.82 (de - 1.08 a - 0.51) = 2.17 -0.82 (de - 1.08 a - 0.51) = 2.17 -0.82 (de - 1.08 a - 0.51) = 2.17 -0.82 (de - 0.73 a - 0.13) = 2.17 -0.83 (de - 0.71 a - 0.01) = 2.14 -0.83 (de - 0.71 a - 0.01) = 2.11 -0.81 (de - 0.71 a - 0.01) = 2.12 Hisra, 2009 -0.82 (de - 0.81 (a - 1.74 a - 0.83) = 2.09 -0.82 (de - 0.81 (a - 1.74 a - 0.83) = 2.09 -0.82 (de - 0.41 a - 2.12) = 0.020; l2 = 2.15 -0.81 (de - 1.74 a - 0.63) = 2.02 -0.82 (de - 0.41 a - 2.17) = 0.020; l2 = 95.8%; p = 0.0001 -0.82 (de - 1.74 a - 0.63) = 2.02 -1.12 (de - 1.38 a - 0.37) = 2.02 -1.11 (de - 1.45 a - 0.77) = 0.000; l2 = 95.8%; p = 0.12 -1.12 (de - 1.38 a - 0.36) = 2.14 -0.000 (de - 0.36 a 0.3	Costa-Ribeiro, 2003	-0.23 (de $-0.58 a -0.48$)	2.14
Jasimski, 2002 -1.43 (de -1.68 a -0.98) 2.10 richtich, 2010 2 = 94.2%; p = 0.0001 2.07 S. boulardii -0.79 (de -1.08 a -0.51) 2.17 Hive, 2006 -1.42 (de -1.68 a -0.98) 2.10 Correa, 2011 -0.43 (de -0.73 a -0.13) 2.17 Daigic, 2011 -0.43 (de -0.73 a -0.13) 2.17 Orrea, 2011 -0.43 (de -0.73 a -0.13) 2.17 -0.35 (de -0.71 a -0.01) 2.14 -0.55 (de -0.73 a -0.13) 2.17 -0.35 (de -0.71 a -0.01) -1.48 (de -2.16 a -0.98) 2.10 -0.88 (de -1.48 a -0.68) 2.12 Illaroue, 2002 -1.03 (de -1.44 a -0.61) 2.11 -0.81 (de -1.07 a -0.55) 16.86 L GG < 10 th CFU -0.81 (de -1.07 a -0.55) 16.86 2.04 0.09 (de -0.06 a 0.25) 2.18 Markow, 1993 -1.22 (de -3.57 a -2.86) 2.04 0.09 (de -0.05 a 0.20) 2.18 Jupont-Pren, 2009 -3.17 (de -1.17 a -0.13) 2.20 -3.17 (de -1.17 a -0.13) 2.20 Vivatvain, 1992 -1.12 (de -1.18 a -0.07) 1.60 2.04 -1.29 (de -1.74 a -0.83) 2.09 Anketovicing, 2002 -1.74 a -0.83 <t< td=""><td>Berni Canari, 2007</td><td>-1.21 (de -1.52 a -0.90)</td><td>2.16</td></t<>	Berni Canari, 2007	-1.21 (de -1.52 a -0.90)	2.16
$\begin{array}{c} \begin{tabular}{lllllllllllllllllllllllllllllllllll$	Jasınski, 2002	-1.43 (de -1.88 a -0.98) 0.02 (de -0.47 a 0.51)	2.10 2.07
S. boulardii Kurogol, 2005 Hive, 2008 Correa, 2011 Dalgic, 2011 Villaruel, 2007 Grandy, 2010 Hafeez, 2002 Bilo, 2006 $L GG < 10^{\circ}$ GFU Guarino, 1997 a = 5.0; p = 0.0001; l2 = 72.1%; p = 0.001 $L GG < 10^{\circ}$ GFU Guarino, 1997 a = 150; p = 0.11; l2 = 97.8%; p = 0.0001 Viabrakin, 1993 a = 5.7; p = 0.0001; l2 = 95.8%; p = 0.0001 a = 5.7; p = 0.0001; l2 = 95.8%; p = 0.0001 L ceuteri RosenfieldIt, 2002 a = 6.34; p = 0.0001; l2 = 95.8%; p = 0.12 L reuteri RosenfieldIt, 2002 Shornikova1, 1997 a = 6.34; p = 0.0001; l2 = 95.8%; p = 0.12 L reuteri RosenfieldIt, 2002 Shornikova1, 1997 a = 6.34; p = 0.0001; l2 = 95.8%; p = 0.12 L reuteri RosenfieldIt, 2002 Shornikova1, 1997 z = 6.34; p = 0.0001; l2 = 95.8%; p = 0.12 L reuteri RosenfieldIt, 2002 Shornikova1, 1997 z = 6.34; p = 0.0001; l2 = 95.8%; p = 0.12 L reuteri RosenfieldIt, 2002 Shornikova1, 1997 z = 6.34; p = 0.0001; l2 = 95.8%; p = 0.0001 a = 12 = (1 + 12 = -0.000); l2 = 95.8%; p = 0.0001 a = 0.12 a = 0.000; l2 = 95.8%; p = 0.0001 a = 0.12 a = 0.000; l2 = 95.8%; p = 0.0001 a = 0.12 a = 0.11; l2 = 0.000; l2 = 95.8%; p = 0.0001 a = 0.12 a = 0.11; l2 = 0.000; l2 = 95.8%; p = 0.0001 a = 0.12 a = 0.11; l2 = 0.000; l2 = 95.8%; p = 0.0001 a = 0.12 a = 0.11; l2 = 0.000; l2 = 95.8%; p = 0.0001 a = 0.12 a = 0.11; l2 = 0.000; l2 = 95.8%; p = 0.0001 a = 0.12 a = 0.000; l2 = 0.200; l0 = 0.200	z = 3.32; p = 0.001; l2 = 94.2%; p = 0.0001	-0.82 (de -0.47 a 0.51)	16.98
$\begin{array}{c} \text{Number 2003} \\ -1.42 \ (de -1.08 \ a -0.51) \ 2.11 \\ \text{Correa, 2011} \\ \text{Vialaruel, 2007} \\ \text{Grandy, 2010} \\ +1.42 \ (de -1.08 \ a -0.98) \ 2.10 \\ -0.43 \ (de -0.73 \ a -0.13) \ 2.17 \\ -0.35 \ (de -0.71 \ a 0.01) \ 2.14 \\ \text{Vialaruel, 2007} \\ -1.42 \ (de -1.63 \ a -0.79) \ 1.94 \\ \text{Hafeez, 2002} \\ +1.03 \ (de -2.12 \ a -0.61) \ 2.11 \\ -0.81 \ (de -1.21 \ a -0.40) \ 2.12 \\ -1.03 \ (de -1.21 \ a -0.61) \ 2.11 \\ -0.81 \ (de -1.07 \ a -0.55) \ 16.86 \\ L \ GG \ -10^{\circ} \ CFU \\ \text{Guarino, 1997} \\ -0.80 \ (de -1.21 \ a -0.61) \ 2.11 \\ -0.81 \ (de -1.07 \ a -0.55) \ 16.86 \\ L \ GG \ -10^{\circ} \ CFU \\ \text{Guarino, 1997} \\ -0.25 \ (de -0.52 \ a 0.20) \ 2.18 \\ -0.86 \ (-1.57 \ a -0.83) \ 2.20 \\ -0.25 \ (de -0.52 \ a 0.20) \ 2.18 \\ -0.86 \ (-1.52 \ a -0.83) \ 2.20 \\ -0.25 \ (de -3.57 \ a -2.86) \ 2.15 \\ -0.88 \ (-1.57 \ a -0.83) \ 2.20 \\ -0.25 \ (de -3.57 \ a -2.86) \ 2.15 \\ -0.88 \ (-1.57 \ a -0.83) \ 2.20 \\ -0.25 \ (de -3.57 \ a -2.86) \ 2.15 \\ -0.88 \ (-1.57 \ a -0.83) \ 2.20 \\ -0.25 \ (de -3.57 \ a -2.86) \ 2.15 \\ -0.88 \ (-1.57 \ a -0.83) \ 2.20 \\ -0.25 \ (de -3.57 \ a -2.86) \ 2.15 \\ -0.88 \ (-1.57 \ a -0.83) \ 2.20 \\ -0.25 \ (de -3.57 \ a -2.86) \ 2.15 \\ -0.88 \ (-1.57 \ a -0.83) \ 2.20 \\ -0.25 \ (de -3.57 \ a -2.86) \ 2.15 \\ -0.88 \ (-1.57 \ a -0.83) \ 2.20 \\ -0.25 \ (de -3.57 \ a -2.86) \ 2.15 \\ -0.88 \ (-1.57 \ a -0.83) \ 2.20 \\ -1.20 \ (de -1.62 \ a -0.57) \ 2.21 \\ -0.81 \ (de -1.62 \ a -0.57) \ 2.21 \\ -0.81 \ (de -1.62 \ a -0.57) \ 2.21 \\ -1.56 \ (de -1.62 \ a -0.57) \ 2.20 \\ -1.56 \ (de -1.62 \ a -0.57) \ 2.20 \\ -1.56 \ (de -1.62 \ a -0.57) \ 2.20 \\ -1.56 \ (de -1.21 \ a -0.11) \ 2.20 \\ -1.56 \ (de -1.21 \ a -0.11) \ 2.20 \\ -1.56 \ (de -1.21 \ a -0.11) \ 2.20 \\ -1.56 \ (de -1.21 \ a -0.17) \ 1.57 \\ -2.57 \ (de -1.57 \ a -0.30) \ 1.57 \\ -2.57 \ (de -1.57 \ a -0.30) \ 1.57 \\ -2.57 \ (de -1.57 \ a -0.30) \ 1.57 \\ -2.57 \ (de -1.57 \ a -0.30) \ 1.57 \\ -2.57 \ (de -1.57 \ a -0.30) \ 1.57 \\ -2.57 \ (de -1.57 \ a -0.37) \ 2.57 \\ -2.57 \ (de -1.55 \ a -0.57) \ 2.57 \\ -2.57 \ (de -1.55 \ a -0.57) \ 2.57 \\ -2.57 \$	S. boulardii	0.70 (do 1.00 o 0.51)	0 17
Correa, 2011 Dalgic, 2011 Ularruel, 2007 Grandy, 2010 Trancevila, 2007 Grandy, 2010 -0.35 (de -0.73 = -0.13) 2.17 -0.35 (de -0.73 = -0.12) 2.11 -0.35 (de -0.71 = 0.01) 2.14 -0.55 (de -0.73 = -0.12) 2.11 -0.35 (de -0.73 = -0.12) 2.11 -0.55 (de -0.37 = -0.12) 2.11 -0.81 (de -1.07 = -0.55) 16.86 -0.81 (de -1.07 = -0.55) 16.86 -0.25 (de -0.52 = 0.02) 2.18 -0.25 (de -0.52 = 0.02) -0.25 (de -0.53 = -2.86) 2.15 -0.26 (de -1.74 = -0.83) 2.21 -0.26 (de -1.74 = -0.83) 2.21 -0.26 (de -1.74 = -0.83) 2.21 -0.26 (de -1.74 = -0.33) 2.21 -0.26 (de -1.62 = -0.55) 2.04 -0.20 (de -0.01; 12 = 95.8%; p 0.0001 -1.04 (de -1.17 = -0.01) 2.20 -0.82 (de -1.62 = -0.25) 2.03 -0.82 (de -1.62 = -0.27) -0.82 (de -1.64 = -0.17) 2.03 -0.82 (de -1.64 = -0.37) 2.07 -0.82 (de -0.04 = -0.30) 2.07 -0.82 (de -0.04 = -0.3	Htwe, 2008	-0.79 (de -1.00 a -0.51) -1.42 (de -1.86 a -0.98)	2.17
Dalgic, 2011 Villarruel, 2007 Grandy, 2010 -0.35 (de -0.71 a 0.01) 2.11 -1.48 (de -2.16 a -0.79) 1.94 Hafeez, 2002 -0.81 (de -1.21 a -0.40) 2.12 -1.03 (de -1.42 a -0.40) 2.12 -0.81 (de -1.07 a -0.55) 16.86 $L GG < 10^{\circ} CFU$ Guarino, 1997 -0.81 (de -1.07 a -0.55) 2.04 -0.80 (de -1.21 a -0.40) 2.12 -0.81 (de -1.07 a -0.55) 16.86 -0.81 (de -0.21 a -0.40) 2.12 -0.81 (de -1.07 a -0.55) 2.04 -0.80 (de -1.21 a -0.40) 2.12 -0.81 (de -1.07 a -0.55) 2.04 -0.88 (-1.97 a 0.20) 6.44 Smactile Dupont-Paru, 2009 -0.25 (de -0.57 a -2.86) 2.15 Madkour, 1993 2 ong $-3.22 (de -3.57 a -2.86)$ 2.15 -1.29 (de -1.74 a -0.83) 2.09 -1.29 (de -1.74 a -0.35) 2.02 -1.08 (de -1.22 a -0.11) 2.03 z = 5.7; p = 0.0001; l2 = 95.8%; p 0.0001 -1.56 (de -2.32 a -1.22) 2.03 Shornikova2, 1997 -0.82 (de -1.57 a -0.30) 1.94 -1.57 (de -4.17 a -0.77) 1.09 -1.57 (de -4.16 a -0.37) 1.97 -0.82 (de -1.46 a -0.17) 1.97 -0.82 (de -1.46 a -0.37) 1.97 -0.82 (de -1.46 a -0.36) 2.04 -0.87 (de -1.36 a -0.37) 1.97 -0.82 (de -1.46 a -0.17) 1.97 -0.82 (de -1.46 a -0.37) 1.97 -0.82 (de -1.46 a -0.36) 2.24 -1.11 (de -0.45 a -0.38) 2.20 -0.12 (de -0.43 a 0.39) 2.21 -0.11 (de -0.43 a 0.39) 2.21 -0.12 (de -0.43 a 0.39) 2.21 -0.12 (de -0.43 a 0.39) 2.16 -0.12 (de -0.03 a 0.28) 2.21 -0.12 (de -0.43 a 0.39) 2.16 -0.12 (de -0.43 a 0.39) 2.16	Correa, 2011	-0.43 (de -0.73 a -0.13)	2.17
$\begin{array}{c} $	Dalgic, 2011	-0.35 (de -0.71 a 0.01)	2.14
Hafeez, 2002 -0.80 (de -1.21 a -0.40) 2.12 Billo, 2006 -1.03 (de -1.45 a -0.61) 2.11 $z = 6.06; p = 0.0001; l2 = 72.1%; p = 0.001$ -0.81 (de -1.07 a -0.55) 16.86 L GG < 10° CFU	Grandy, 2010 —	-1.48 (de -2.16 a -0.79)	1.94
Billo, 2006 z = 6.06; p = 0.0001; l2 = 72.1%; p = 0.001 $L = GG < 10^{\circ} CFU$ Guarino, 1997 Gaurino, 1997 Gaurino, 2009 $z = 1.59; p = 0.11; l2 = 97.8%; p = 0.0001Since CiteDupont-Peru, 2009Colored Cite Cite Cite Cite Cite Cite Cite Cite$	Hafeez, 2002	-0.80 (de -1.21 a -0.40)	2.12
$ \begin{array}{c} L \ {\rm GG} < 10^{\rm m} \ {\rm CFU} \\ {\rm Guarino, 1997} \\ {\rm Basu, 2007} \\ {\rm Misra, 2009} \\ z = 1.59; {\rm p} = 0.11; 12 = 97.8\%; {\rm p} = 0.0001 \\ \end{array} $	Billo, 2006 z = 6.06; p = 0.0001; l2 = 72.1%; p = 0.001	-1.03 (de -1.45 a -0.61) -0.81 (de -1.07 a -0.55)	2.11 16.86
Guarino, 1997 -2.60 (de $-3.14 a - 2.06$) 2.24 Misra, 2009 -0.25 (de $-0.52 a 0.02$) 2.18 Jugont-Peru, 2009 -0.25 (de $-0.52 a 0.02$) 2.18 Smectite -0.25 (de $-0.52 a 0.02$) 2.18 Dupont-Peru, 2009 -0.25 (de $-0.57 a -2.86$) 2.15 Madkour, 1993 -1.29 (de $-1.74 a -0.83$) 2.09 Zong, 1997 -4.80 (de $-6.27 a -3.33$) 1.32 Lachaux, 1986 -1.17 (de $-4.17 a -2.17$) 1.69 Vivatakin, 1992 -1.08 (de $-1.62 a -0.55$) 2.04 Guarino, 2001 -1.06 (de $-1.84 a -1.28$) 2.18 Narkeviciute, 2002 -1.06 (de $-1.21 a -0.11$) 2.03 Shornikova2, 1997 -0.66 (de $-1.21 a -0.17$) 1.97 Rosenfeldt1, 2002 -0.87 (de $-1.56 a -0.37$) 2.07 Post (de $-1.56 a -0.37$) 2.07 -0.87 (de $-1.66 a -0.37$) 2.07 Shornikova1, 1997 -0.82 (de $-1.46 a -0.17$) 1.97 -0.82 (de $-1.66 a -0.37$) 2.07 Shornikova1, 2005 -0.001 (l $2 = 44.8\%; p = 0.12$ -0.87 (de $-0.36 a 0.36$) 2.14 Brooks 2, 2005 0.00 (de $-0.36 a 0.36$) 2.14 <	L GG < 10 ¹⁰ CFU		
Data J. 2009 $-0.25 (de -0.52 a 0.02)$ 2.18 $z = 1.59; p = 0.11; l2 = 97.8\%; p = 0.0001$ $-0.25 (de -0.52 a 0.02)$ 2.18 Smectite $-0.25 (de -0.52 a 0.02)$ 6.44 Smectite $-0.25 (de -0.52 a 0.02)$ 6.44 Smectite $-0.88 (-1.97 a 0.20)$ 6.44 Support Peru, 2009 $-3.22 (de -3.57 a -2.86)$ 2.15 Madkour, 1993 $-1.29 (de -1.74 a -0.83)$ 2.09 Zong, 1997 $-4.80 (de -6.27 a -3.33)$ 1.32 Lachaux, 1986 $-1.06 (de -1.26 a -0.55)$ 2.04 Markeviciute, 2002 $-1.06 (de -1.24 a -0.11)$ 2.03 Purderi $-0.66 (de -1.21 a -0.11)$ 2.03 Narkeviciute, 2002 $-0.94 (de -1.57 a -0.30)$ 1.97 Posenfeldt1, 2002 $-0.87 (de -1.36 a -0.37)$ 2.07 Shornikova1, 1997 $-1.12 (de -1.65 a -0.59)$ 2.04 Zra < 6 months	Guarino, 1997 – Basu 2007	-2.60 (de -3.14 a -2.06) 0.09 (de -0.06 a 0.25)	2.04 2.21
z = 1.59; p = 0.11; 2 = 97.8%; p = 0.0001 -0.88 (-1.97 a 0.20) 6.44 Smectite Dupont-Peru, 2009 Addition, 1993 Lachaux, 1996 Vivatvakin, 1992 Lachaux, 1986 Vivatvakin, 1992 Lachaux, 1986 Vivatvakin, 1992 Lachaux, 1986 Vivatvakin, 1992 Lachaux, 1986 -3.22 (de -3.57 a -2.86) 2.15 -1.29 (de -1.74 a -0.83) 2.09 -4.80 (de -6.27 a -3.33) 1.32 -3.17 (de -4.17 a -2.17) 1.69 -4.80 (de -6.22 a -3.33) 1.32 -3.17 (de -4.17 a -2.17) 1.69 -4.80 (de -6.22 a -3.33) 1.32 -3.17 (de -4.17 a -2.17) 1.69 -4.80 (de -6.22 a -3.33) 1.32 -3.17 (de -4.17 a -2.17) 1.69 -4.80 (de -6.22 a -3.33) 1.32 -3.17 (de -4.17 a -2.17) 1.69 -4.80 (de -6.22 a -3.33) 1.32 -3.17 (de -4.17 a -2.17) 1.59 -4.80 (de -1.62 a -0.55) 2.04 -1.08 (de -1.21 a -0.11) 2.03 -1.95 (de -2.62 a -1.27) 15.72 -1.12 (de -1.65 a -0.59) 2.04 -0.82 (de -1.46 a -0.17) 1.97 -0.94 (de -1.57 a -0.30) 1.98 Francavilla, 2012 -1.12 (de -1.65 a -0.59) 2.04 -0.11 (de -0.05 a 0.36) 2.14 Brooks 2, 2005 -1.12 (de -0.36 a 0.36) 2.14 Brooks 1, 2006 -1.11 (de -0.05 a 0.28) 2.21 Fisher-Walker FTH, 2006 Fisher-Walker ETH, 2006 Fisher-Walker ETH, 2006 Fisher-Walker ETH, 2006 -1.12 (de -0.05 a 0.28) 2.21 Fisher-Walker ETH, 2006 -1.12 (de -0.05 a 0.28) 2.21 Fisher-Walker ETH, 2006 -0.12 (de -0.01 a 0.40) 2.20 z = 1.61; p = 0.10; 2 = 97.2%; p = 0.0001 -1.12 (de -1.39 a -0.86) 100.00 Note: weights are from random effects analyses	Misra, 2009	-0.25 (de -0.52 a 0.02)	2.18
Smectite -3.22 (de $-3.57 a - 2.86$) 2.15 Dupont-Peru, 2009 -4.80 (de $-6.27 a - 3.33$) 1.32 Lachaux, 1986 -3.17 (de $-1.74 a - 0.83$) 2.09 Vivatvakin, 1992 -3.17 (de $-1.74 a - 0.83$) 2.09 Guarino, 2001 -1.08 (de $-6.27 a - 3.33$) 1.32 Dupont-Malasia, 2009 -1.08 (de $-1.62 a - 0.55$) 2.04 Markeviciute, 2002 -1.06 (de $-1.21 a - 0.11$) 2.03 z = 5.7; p = 0.0001; l2 = 95.8%; p 0.0001 -1.56 (de $-1.21 a - 0.11$) 2.03 Shornikovaz, 1997 -0.66 (de $-1.21 a - 0.11$) 2.03 Shornikovaz, 1997 -0.87 (de $-1.62 a - 0.57$) 2.04 Rosenfeldt1, 2002 -0.67 (de $-1.36 a - 0.77$) 1.97 Shornikovaz, 1997 -0.87 (de $-1.62 a - 0.59$) 2.04 Francavilla, 2012 -0.87 (de $-1.63 a - 0.37$) 2.07 Shornikovaz, 1997 -1.12 (de $-1.63 a - 0.59$) 2.04 z = 6.34; p = 0.001; l2 = 44.8%; p = 0.12 -0.67 (de $-1.36 a - 0.37)$ 2.07 Zinc < 6 months	z = 1.59; p = 0.11; l2 = 97.8%; p = 0.0001	-0.88 (-1.97 a 0.20)	6.44
Madkour, 1993 -1.29 (de $-1.74 a - 0.83$) 2.09 Zong, 1997 -4.80 (de $-6.27 a - 3.33$) 1.32 Lachaux, 1986 -3.17 (de $-4.17 a - 2.17$) 169 Vivatvakin, 1992 -1.08 (de $-1.62 a - 0.55$) 2.04 Guarino, 2001 -1.06 (de $-1.21 a - 0.11$) 2.03 Dupont-Malasia, 2009 -1.56 (de $-1.84 a - 1.28$) 2.18 Narkeviciute, 2002 -0.66 (de $-1.21 a - 0.11$) 2.03 z = 5.7; p = 0.0001; l2 = 95.8%; p 0.0001 -1.76 (de $-2.32 a - 1.20$) 2.03 Shornikova2, 1997 -0.82 (de $-1.46 a - 0.77$) 15.72 L reuteri -0.68 (de $-1.57 a - 0.30$) 1.98 Francavilla, 2012 -0.76 (de $-2.32 a - 1.20$) 2.03 Shornikova2, 1997 -0.82 (de $-1.46 a - 0.77$) 1.97 Rosenfeldt1, 2002 -0.87 (de $-1.36 a - 0.37$) 2.07 Shornikova1, 1997 -0.82 (de $-1.46 a - 0.77$) 10.09 z = 6.34; p = 0.001; l2 = 44.8%; p = 0.12 -1.11 (de $-1.45 a - 0.59$) 2.04 Z = 0.55 2.005 0.00 (de $-0.36 a 0.36$) 2.14 Brooks 1, 2005 0.00 (de $-0.36 a 0.36$) 2.14 Fisher-Walker PAK, 2006	Smectite Dupont-Peru, 2009	-3.22 (de -3.57 a -2.86)	2.15
2016, 1997 -4.80 ($de - 0.27 a - 3.33$) 1.32 Lachaux, 1986 -3.17 ($de - 4.17 a - 2.17$) 1.69 Vivatvakin, 1992 -1.08 ($de -1.62 a - 0.55$) 2.04 Guarino, 2001 -1.08 ($de -1.62 a - 0.55$) 2.04 Dupont-Malasia, 2009 -1.56 ($de -1.21 a - 0.11$) 2.03 Narkeviciute, 2002 -1.56 ($de -2.32 a -1.20$) 2.03 Shornikova2, 1997 -0.82 ($de -1.46 a - 0.17$) 1.97 Rosenfeldt1, 2002 -0.82 ($de -1.46 a - 0.17$) 1.97 Francavilla, 2012 -0.87 ($de -1.36 a - 0.37$) 2.03 Francavilla, 2012 -0.87 ($de -1.36 a - 0.37$) 2.07 Shornikova1, 1997 -0.87 ($de -1.36 a - 0.37$) 2.07 Shornikova1, 1997 -0.87 ($de -1.46 a - 0.77$) 10.09 Zinc < 6 months	Madkour, 1993	-1.29 (de -1.74 a -0.83)	2.09
Vivatvakin, 1992 -1.08 (de -1.62 a -0.55) 2.04 Guarino, 2001 -1.04 (de -1.19 a -0.90) 2.21 Dupont-Malasia, 2009 -1.56 (de -1.21 a -0.11) 2.03 sarkeviciute, 2002 -1.56 (de -2.32 a -1.27) 15.72 <i>L reuteri</i> -0.66 (de -1.21 a -0.11) 2.03 Rosenfeldt1, 2002 -0.82 (de -1.46 a -0.17) 197 Rosenfeldt2, 2002 -0.84 (de -1.59 a -0.30) 1.98 Francavilla, 2012 -0.87 (de -1.36 a -0.37) 2.07 Shornikova1, 1997 -0.87 (de -1.46 a -0.77) 10.09 Zinc < 6 months	Lachaux. 1986	-4.60 (de -6.27 a -3.33) -3.17 (de -4.17 a -2.17)	1.62
Guarno, 2001 -1.04 (de $-1.9 a - 0.90$) 2.21 Dupont-Malasia, 2009 -1.56 (de $-1.21 a - 0.11$) 2.03 sarkeviciuite, 2002 -1.95 (de $-2.62 a - 1.27$) 15.72 L reuteri -0.66 (de $-1.21 a - 0.11$) 2.03 Rosenfeldt1, 2002 -0.82 (de $-1.46 a - 0.17$) 197 Rosenfeldt2, 2002 -0.87 (de $-1.36 a - 0.37$) 198 Francavilla, 2012 -0.87 (de $-1.36 a - 0.59$) 2.04 Shornikova1, 1997 -0.87 (de $-1.46 a - 0.77$) 10.09 Z = 6.34; p = 0.001; l2 = 44.8%; p = 0.12 -1.11 (de $-1.45 a - 0.37$) 2.07 Shornikova1, 1997 -1.12 (de $-1.65 a - 0.59$) 2.04 z = 6.34; p = 0.001; l2 = 44.8%; p = 0.12 -1.11 (de $-1.46 a - 0.77$) 10.09 Zinc < 6 months	Vivatvakin, 1992	-1.08 (de -1.62 a -0.55)	2.04
Deprint matching, 2003 -1.50 (de -1.24 a -1.20) 2.16 Narkeviciuity, 2002 -0.66 (de -1.21 a -0.11) 2.03 $z = 5.7; p = 0.0001; l2 = 95.8%; p 0.0001$ -1.76 (de -2.32 a -1.20) 2.03 Shornikova2, 1997 -0.82 (de -1.46 a -0.17) 197 Rosenfeldt1, 2002 -0.87 (de -1.36 a -0.37) 1.98 Francavilla, 2012 -0.87 (de -1.36 a -0.37) 2.07 Shornikova1, 1997 -0.87 (de -1.46 a -0.77) 10.09 Zinc < 6 months	Guarino, 2001	-1.04 (de -1.19 a-0.90)	2.21
z = 5.7; p = 0.0001; l2 = 95.8%; p 0.0001 $ -1.95 (de -2.62 a -1.27) $ $ 15.72 $ $ L reuteri $ Rosenfeldt1, 2002 Shornikova2, 1997 Rosenfeldt2, 2002 Francavilla, 2012 Shornikova1, 1997 z = 6.34; p = 0.001; l2 = 44.8\%; p = 0.12 $ -1.76 (de -2.32 a -1.20) 2.03 -0.82 (de -1.46 a -0.17) 1.97 -0.82 (de -1.56 a -0.37) 2.07 Shornikova1, 1997 z = 6.34; p = 0.001; l2 = 44.8\%; p = 0.12 $ $ -1.11 (de -1.45 a -0.37) 2.07 -1.12 (de -1.65 a -0.59) 2.04 -1.11 (de -0.45 a -0.36) 2.14 Brooks 1, 2005 Brooks 1, 2005 Fisher-Walker PAK, 2006 Fisher-Walker IND, 2006 z = 1.61; p = 0.11; l2 = 0.0\%; p = 0.49 z = 8.32; p = 0.0001; l2 = 97.2\%; p = 0.0001 Note: weights are from random effects analyses -1.12 (de -1.39 a -0.86) 100.00 $	Narkeviciute, 2002	-0.66 (de -1.21 a -0.11)	2.03
L reuteri Rosenfeldt1, 2002 Shornikova2, 1997 Rosenfeldt2, 2002 Francavilla, 2012 Francavilla, 2012 Shornikova1, 1997 Shornikova1, 1997 $z = 6.34; p = 0.001; l2 = 44.8%; p = 0.12$ Zinc < 6 months	z = 5.7; p = 0.0001; l2 = 95.8%; p 0.0001	-1.95 (de -2.62 a -1.27)	15.72
Shornikova2, 1997 -0.82 (de -1.46 a -0.17) 1.97 Rosenfeldt2, 2002 -0.94 (de -1.57 a -0.30) 1.98 Francavilla, 2012 -0.87 (de -1.36 a -0.37) 2.07 Shornikova1, 1997 -0.87 (de -1.36 a -0.37) 2.07 Shornikova1, 1997 -0.87 (de -1.36 a -0.37) 2.07 Shornikova1, 1997 -1.12 (de -1.65 a -0.59) 2.04 z = 6.34; p = 0.001; l2 = 44.8%; p = 0.12 -1.11 (de -1.45 a -0.77) 10.09 Zinc < 6 months	L. reuteri Rosenfeldt1, 2002 –	-1.76 (de -2.32 a -1.20)	2.03
Hosemenduz, 2002 -0.94 (de $-1.57 a - 0.30$) 198 Francavilla, 2012 -0.87 (de $-1.57 a - 0.37$) 2.07 Shornikova1, 1997 -1.12 (de $-1.65 a - 0.59$) 2.04 z = 6.34; p = 0.001; l2 = 44.8%; p = 0.12 -1.11 (de $-1.45 a - 0.77$) 10.09 Zinc < 6 months	Shornikova2, 1997	-0.82 (de -1.46 a -0.17)	1.97
Shornikova1, 1997 -1.12 (de $-1.65 a - 0.59)$ 2.04 z = 6.34; p = 0.001; l2 = 44.8%; p = 0.12 -1.12 (de $-1.65 a - 0.59)$ 2.04 Zinc < 6 months	Hosenteiot2, 2002	-0.94 (de -1.57 a -0.30) -0.87 (de -1.36 a -0.37)	1.98 2 07
z = 6.34; p = 0.001; 2 = 44.8%; p = 0.12 $-1.11 (de -1.45 a -0.77)$ 10.09 Zinc < 6 months	Shornikova1, 1997	-1.12 (de -1.65 a -0.59)	2.04
Zinc < 6 months	z = 6.34; p = 0.001; l2 = 44.8%; p = 0.12	-1.11 (de -1.45 a -0.77)	10.09
Brooks 1, 2005 $0.00 (de -0.36 a 0.36)$ 2.14 Fisher-Walker PAK, 2006 $0.11 (de -0.05 a 0.28)$ 2.21 Fisher-Walker IND, 2006 $-0.12 (de -0.43 a 0.19)$ 2.16 $z = 1.61; p = 0.11; l2 = 0.0\%; p = 0.49$ $0.09 (de -0.02 a 0.20)$ 10.86 $z = 8.32; p = 0.0001; l2 = 97.2%; p = 0.0001$ $-1.12 (de -1.39 a -0.86)$ 100.00 Note: weights are from random effects analyses $-1.12 (de -1.39 a -0.86)$ 100.00	Zinc < 6 months Brooks 2, 2005	0.00 (de -0.36 a 0.36)	2.14
risner-warker PAR, 2006 0.11 (de $-0.05 a 0.28$) 2.21 Fisher-Walker ETH, 2006 $-0.12 (de -0.43 a 0.19)$ 2.16 Fisher-Walker IND, 2006 0.20 (de $-0.01 a 0.40$) 2.20 z = 1.61; p = 0.11; l2 = 0.0%; p = 0.49 0.09 (de $-0.02 a 0.20$) 10.86 z = 8.32; p = 0.0001; l2 = 97.2%; p = 0.0001 $-1.12 (de -1.39 a -0.86)$ 100.00 Note: weights are from random effects analyses $-1.12 (de -1.39 a -0.86)$ 100.00	Brooks 1, 2005	0.00 (de -0.36 a 0.36)	2.14
Fisher-Walker IND, 2006 0.20 (de -0.01 a 0.40) 2.20 z = 1.61; p = 0.11; l2 = 0.0%; p = 0.49 0.09 (de -0.02 a 0.20) 10.86 z = 8.32; p = 0.0001; l2 = 97.2%; p = 0.0001 -1.12 (de -1.39 a -0.86) 100.00 Note: weights are from random effects analyses -1.12 (de -1.39 a -0.86) 100.00	Fisher-Walker ETH, 2006	0.11 (de –0.05 a 0.28) –0.12 (de –0.43 a 0.19)	2.21
z = 1.61; p = 0.11; l2 = 0.0%; p = 0.49 0.09 (de -0.02 a 0.20) 10.86 z = 8.32; p = 0.0001; l2 = 97.2%; p = 0.0001 -1.12 (de -1.39 a -0.86) 100.00 Note: weights are from random effects analyses 100.00 100.00	Fisher-Walker IND, 2006	0.20 (de -0.01 a 0.40)	2.20
z = 8.32; p = 0.0001; l2 = 97.2%; p = 0.0001	z = 1.61; p = 0.11; l2 = 0.0%; p = 0.49	0.09 (de -0.02 a 0.20)	10.86
	z = 8.32; p = 0.0001; l2 = 97.2%; p = 0.0001	-1.12 (de -1.39 a -0.86)	100.00

Figure 2. Meta-analisis of direct comparisons.

Table 1. Characteristics of direct com	iparisons and their imp	act on diarrnea duration	on	
Comparison	Active group (n)	Placebo group (n)	SMD (95% CI)	z-value (p)
Racecadotril vs. placebo	699	685	-3.33 (-5.13 to -1.52)	3.61 (0.0001)
Smectite vs. placebo	948	951	-1.95 (-2.62 to -1.27)	5.70 (0.0001)
L. GG > 10^{10} CFU vs. placebo	1,129	1,315	-0.82 (-1.31 to -0.34)	3.32 (0.001)
L. GG $\leq 10^{10}$ CFU vs. placebo			-0.88 (-1.97 to 0.20)	1.59 (0.11)
S. boulardii vs. placebo	596	596	-0.81 (-1.07 to -0.55)	6.05 (0.001)
L. reuteri vs. placebo	133	154	-1.11 (-1.45 to -0.77)	6.34 (0.001)
Zinc vs. placebo (≤ 6 months)	625	709	0.09 (-0.02 to 0.20)	1.61 (0.11)
Zinc vs. placebo (> 6 months)	1,086	1,089	-0.20 (-0.41 to 0.00)	1.92 (0.05)



Figure 3. Meta-analysis of direct and indirect comparisons of coadjuvant agents in the treatment of acute diarrhea in children younger than 5 years.

identified between studies, with similar differences when both the size of effect of the standard error and the effect of specific comparisons were observed, which allows for the robustness of the model and the conclusions indicated in the multiple-treatment meta-analysis to be supporterd (Fig. 4).



Figure 4. Funnel plot of multiple comparisons.



Figure 5. Best treatment assesment.

Finally, using data of the previous analyses both from direct and indirect comparisons, we established a relative arrangement model using the SUCRA command of STAT 12.0 in order to identify the first best treatment according to the analyzed primary outcome, and we indentified racecadotril as being at first place, with a value of 9.0, followed by smectite (7.0) and, in third place, *L. reuteri* (6.0) (Fig. 5).

Discussion and conclusions

Acute gastroenteritis remains as an important cause of morbidity and mortality among children, especially in countries with limited resources. Although there is a significant proportion of mild and self-limited cases, it represents an important cause for hospitalization and is associated with significant burden of disease^{78,79}.

Analyzed from a global perspective, it acquires a huge importance from the public health point of view if we consider that it generates approximately 20% of all deaths ocurring in children younger than 5 years in the world⁸⁰.

Despite the intense promotion to consider oral rehydration solutions as the cornerstone of treatment, less than 20% of children with acute gastroenteritis are estimated to optimally receive a preventive or therapeutic regimen for this type of problems, which entails high rates of hospitalization, complications, long hospital stays and significantly high direct and indirect costs⁸¹. So, only in the USA, this disease is estimated to generate 1.5 million visits to the doctor/year, 220,000 hospitalizations (10% of all hospital admissions in USA) and very significant figures of school and workplace absenteeism⁸².

Even though oral hydration regimens with reduced osmolarity solutions continue to be regarded as the cornerstone of treatment, all this has motivated to increasingly insist on the need for therapeutic coadjuvants based on scientific evidence with methodological rigour that allow, in an additive or synergistic manner, evolution of this type of conditions to be favored and, therefore, complications, mortality and hospitalizations to be reduced, as well as the associated economic impact⁸³.

Unlike previous publications, including traditional systematic reviews with meta-analyses of pair-wise comparations that generally have made contrasts of different adjuvant agents with placebo, the originality of the present proposal lies in the fact that it includes analyses not only of direct comparisons (coadjuvant agent vs. placebo), but even of unpublished or indirect comparisons (e.g., racecadrotil vs. smectite; smectite vs. *L. reuteri*), which robustly allow for decision-making policies on the best coadjuvant therapy or therapies to be established⁸⁴⁻⁸⁸.

The results of this multiple-comparison meta-analysis allow, first of all, to observe the effect of different coadjuvant agents when compared with placebo, but at the same time they allow, in second place, to graphically and mathematically visualize the effects generated

when indirect comparisons of coadjuvants to each other are performed, thus immediately identifying the superiority that in the first place racecadotril can have, followed by smectite and then the therapeutic equivalence of other coadjuvant agents with each other, such as the administration of S. boulardii, L. reuteri at high doses (> 10¹⁰ CFU), *L. reuteri* or zinc in children older than 6 months. In parallell and concordantly, by performing the SUCRA analysis, which in one way or another weighs the number of published trials, the sample size in each one of them and within the type of coadjuvant agent, methodological quality of the designs, as well as significance and robustness of the reported results, we can confirm the superiority of racecadotril as a coadjuvant for the management of this condition, closely followed by the administration of smectite or L. reuteri. We consider that this type of analysis and results are significantly useful for the decision-maker in order to, under cost-effectiveness and risk-benefit criteria, be able to objectively rely on for an efficient health-related decision-making process.

References

- Payne DC, Vinje J, Szilagyi PG, et al. Norovirus and medically attended gastroenteritis in U.S. children. N Engl J Med. 2013;368(12):1121-30.
- Liu L, Johnson HL, Cousens S, et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet. 2012;379(9832):2151-61.
- Freedman SB, Steiner MJ, Chan KJ. Oral ondansetron administration in emergency departments to children with gastroenteritis: an economic analysis. PLoS Med. 2010;7(10). pii: e1000350.
- Malek MA, Curns AT, Holman RC, et al. Diarrhea- and rotavirus-associated hospitalizations among children less than 5 years of age: United States, 1997 and 2000. Pediatrics. 2006;117(6):1887-92.
- Majowicz SE, McNab WB, Sockett P, et al. Burden and cost of gastroenteritis in a Canadian community. J Food Prot. 2006;69(3):651-9.
- Dennehy PH. Acute diarrheal disease in children: epidemiology, prevention, and treatment. Infect Dis Clin North Am. 2005;19(3):585.
- Powell EC, Hampers LC. Physician variation in test ordering in the management of gastroenteritis in children. Arch Pediatr Adolesc Med. 2003;157(10):978-83.
- Freedman SB, Gouin S, Bhatt M, et al. Prospective assessment of practice pattern variations in the treatment of pediatric gastroenteritis. Pediatrics. 2011;127(2):E287-95.
- Freedman SB, Sivabalasundaram V, Bohn V, Powell EC, Johnson DW, Boutis K. The treatment of pediatric gastroenteritis: a comparative analysis of pediatric emergency physicians' practice patterns. Acad Emerg Med. 2011;18(1):38-45.
- Kinlin LM, Bahm A, Guttmann A, Freedman SB. Department resources and strategies employed in the treatment of pediatric gastroenteritis. Acad Emerg Med. 2013;20(4):361-6.
- Farthing M, Salam MA, Lindberg G, et al. Acute diarrhea in adults and children: a global perspective. J Clin Gastroenterol. 2013;47(1): 12-20.
- Gonzales SC, Bada MC, Rojas GR, Bernaola AG, Chávez BC; Instituto Nacional de Salud del Niño. [Clinical practice guidelines on the diagnosis and treatment of infectious acute diarrhea in children Peru – 2011]. Rev Gastroenterol Peru. 2011;31(3):258-77.
- Salazar-Lindo E, Polanco Allué I, Gutiérrez-Castrellón P; Grupo Ibero-Latinoamericano sobre el Manejo de la Diarrea Aguda (GILA). Guía de práctica clínica ibero-latinoamericana sobre el manejo de la gastroenteritis aguda en menores de 5 años: tratamiento farmacológico. An Pediatr (Barc). 2014;80 Suppl 1:15-22.
- Gutiérrez Castrellón P, Polanco Allué I, Salazar Lindo E. JAn evidence based Iberic-Latin American guideline for acute gastroenteritis management in infants and prescholars]. An Pediatr (Barc). 2010;72(3):220. e1-220.e20.

- Pie'scik-Lech M, Shamir R, Guarino A, Szajewska H. Review article: the management of acute gastroenteritis in children. Aliment Pharmacol Ther. 2013;37(3):289-303.
- Guarino A, Albano F, Ashkenazi S, et al. European Society for Paediatric Gastroenterology, Hepatology, and Nutrition/European Society for Paediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe. J Pediatr Gastroenterol Nutr. 2008;46 Suppl 2:S81-122.
- Wong SS1, Wilczynski NL, Haynes RB. Comparison of top performing search strategies for detecting clinically sound treatment studies and systematic reviews in MEDLINE and EMBASE. J Med Libr Assoc. 2006 Oct;94(4):451-5.
- Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (eds). Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration, 2011. [Internet] Disponible en: http://www.cochrane-handbook.org.
- Purgato M, Barbui C, Cipriani A. Assessing risk of bias in randomized controlled trials. Epidemiol Psichiatr Soc. 2010;19(4):296-7.
- Scott, G (2001). Strategic Planning for High-Tech Product Development. Technology Analysis & Strategic Management, Vol. 13, No. 3.
- 21. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23(20):3105-24.
- Ades AE, Sculpher M, Sutton A, et al. Bayesian methods for evidence synthesis in cost-eff ectiveness analysis. Pharmacoeconomics. 2006;24(1):1-19.
- Salanti G, Higgins JP, Ades AE, Ioannidis JP. Evaluation of networks of randomized trials. Stat Methods Med Res. 2008;17(3):279-301.
- Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(2):163-71.
- Salanti G, Marinho V, Higgins JP. A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered. J Clin Epidemiol. 2009;62(8):857-64.
- Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010;29(7-8):932-44.
- Salazar-Lindo E, Santisteban-Ponce J, Chea-Woo E, Gutierrez M. Racecadotril in the treatment of acute watery diarrhoea in children. N Engl J Med. 2000;343(7):463-7.
- Cezard JP, Duhamel JF, Meyer M, et al. Efficacy and tolerability of racecadotril in gastroenteritis in children. Gastroenterology. 2001;120(4): 799-805.
- Cojocaru B, Bocquet N, Timsit S, et al. Effet du racécadotril sur le recours aux soins dans le traitement des diarrhées aiguës du nourrisson et de l'enfant. Arch Pédiatr. 2002;9(8):774-9.
- Savitha MR. Racecadotrial a novel drug for treatment of acute watery diarrhoea in Indian children. Karnataka Pedicon 2005-Conference Abstracts. Pediatric Oncall; 2006 [Internet] Consultado el 1 de enero de 2006. Disponible en: http://www.pediatriconcall.com/fordoctor/.
- Santos M, Marañón R, Miguez C, Vázquez P, Sánchez C. Use of racecadotril as outpatient treatment for acute gastroenteritis:a prospective, randomized, parallel study. J Paediatr. 2009;155(1):62-7.
 Alvarez Calatayud G, Pinel G, Taboada L, et al. Efectividad de raceca-
- Alvarez Calatayud G, Pinel G, Taboada L, et al. Efectividad de racecadotrilo en el tratamiento de la gastroenteritis aguda. Acta Pediatr Esp. 2009;67:177-22.
- 33. Gutiérrez-Castrellón P, Acosta-Bastidas M, Llamosas Gallardo B, et al. Ensayo clínico aleatorizado y análisis farmaco económico del impacto de racecadotrilo (Hidrasec[®]) como coadyuvante en el tratamiento de la gastroenteritis aguda sobre la reducción de los gastos hospitalarios relacionados en lactantes menores de 24 meses en México. Gac Med Mex. 2014 (in press).
- Melendez Garcia JM, Rodriguez JT. Racecadotril en el tratamiento de la diarrea aguda en niños. Rev Facultad Med (Guatemala). 2007;4:25-8.
- Vivatvakin B, Jongpipatvanich S, Harikul S, Eksaengri P, Lortholary O. Control study of oral rehydration solution (ORS)/ORS + dioctahedral smectite in hospitalized Thai infants with acute secretory diarrhea. Southeast Asian J Trop Med Public Health. 1992;23(3):414-9.
- Narkeviciute I, Rudzeviciene O, Leviniene G, Mociskiene K, Eidukevicius R. Management of Lithuanian children's acute diarrhoea with Gastrolit solution and dioctahedral smectite. Eur J Gastroenterol Hepatol. 2002;14(4):419-24.
- Zong S, Chao YM, Qu Y, Liu L. Study on Smecta therapy for acute diarrhea in infants. J Tianjing Med Univ. 1997;3:60-3.
- Madkour AA, Madina ÉMH, El-Azzouni OEZ, Amer MA, El-Walili TMK, Abbass T. Smectite in acute diarrhoea in children: a double-blind placebo-controlled clinical trial. J Pediatr Gastroenterol Nutr. 1993;17(2): 176-81.
- Lachaux A, Danzon A, Collet JP, Descos B, Hermier M. Acute infantile diarrhoea. Role of treatment with smectite as complement to rehydration. Randomised double-blind study. Int Rev Pediatr. 1986;163:29-31.
- Guarino A, Bisceglia M, Castellucci G, et al. Italian Society of Pediatric Gastroenterology and Hepatology Study Group for Smectite in Acute

Diarrhea. Smectite in the treatment of acute diarrhea: a nationwide randomized controlled study of the Italian Society of Pediatric Gastroenterology and Hepatology (SIGEP) in collaboration with primary care pediatricians. SIGEP Study Group for Smectite in Acute Diarrhea. J Pediatr Gastroenterol Nutr. 2001;32(1):71-5.

- Gilbert B, Lienhardt A, Palomera S, Barberis L, Borreda D. A study of the effectiveness of smectite versus placebo or loperamide in acute infantile diarrhoea. Ann Pediatr (Paris). 1991;38(9):633-6.
- Osman GAH, Mahomoud SAR, El-Shakankiry HM, Abulhana SM. An adsorbent! Role in the management of acute diarrea in infants and children. Ain Shams Med J. 1992;13:10, 11 and 12665-76.
- Lexomboon U, Harikul S, Lorthola O. Control randomized study of rehydration/ rehydration with dioctahedral smectite in ambulatory Thai infants with acute diarrhoea. Southeast Asian J Trop Med Public Health. 1994;25(1):157-62.
- DuPont C, Moreno JL, Barau E, Bargaoui K, Thiane E, Plique O. Effect of diosmectite on intestinal permeability changes in acute diarrhea: a doubleblind placebo-controlled trial. J Pediatr Gastroenterol Nutr. 1992;14(4):413-9.
- Mujawar QM, Naganoor R, Ali MD, Malagi N, Thobbi AN. Efficacy of dioctahedral smectite in acute watery diarrhea in indian children: a randomized clinical trial. J Trop Pediatr. 2012;58(1):63-7.
 Costa-Ribeiro H, Ribeiro TC, Mattos AP, et al. Limitations of probiotic
- Costa-Ribeiro H, Ribeiro TC, Mattos AP, et al. Limitations of probiotic therapy in acute, severe dehydrating diarrhea. J Pediatr Gastroenterol Nutr. 2003;36(1):112-5.
- Guandalini S, Pensabene L, Zikri MA, et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J Pediatr Gastroenterol Nutr. 2000;30(1): 54-60.
- Shornikova AV, Isolauri E, Burkanova L, Lukovnikova S, Vesikari T. A trial in the Karelian Republic of oral rehydration and Lactobacillus GG for treatment of acute diarrhea. Acta Paediatr. 1997;86(5):460-5.
- Jasinski C, Tanzi MN, Schelotto F, et al. Efficacy of Lactobacillus GG in oral rehydration solution. Pediátrica. 2002;22:231-43.
- Canani RB, Cirillo P, Terrin G, et al. Probiotics for treatment of acute diarrhea in children: randomised clinical trial of five different preparations. BMJ. 2007;335(7615):340.
- Ritchie BK, Brewster DR, Tran CD, Davidson GP, McNeil Y, Butler RN. Efficacy of Lactobacillus GG in aboriginal children with acute diarrheal disease: a randomised clinical trial. J Pediatr Gastroenterol Nutr. 2010;50(6):619-24.
- Isolauri E, Kaila M, Mykkänen H, Ling WH, Salminen S. Oral bacteriotherapy for viral gastroenteritis. Dig Dis Sci. 1994;39(12):2595-600.
- Basu S, Paul DK, Ganguly S, Chatterjee M, Chandra PK. Efficacy of high-dose Lactobacillus rhamnosus GG in controlling acute watery diarrhea in Indian children: a randomized controlled trial. J Clin Gastroenterol. 2009;43(3):208-13.
- Basu S, Chatterjee M, Ganguly S, Chandra PK. Efficacy of Lactobacillus rhamnosus GG in acute watery diarrea of Indian children: a randomized controlled trial. J Paediatr Child Health. 2007;43(12):837-42.
- Misra S, Sabui TK, Pal NK. A randomized controlled trial to evaluate the efficacy of Lactobacillus GG in infantile diarrhea. J Pediatr. 2009;155(1):129-32.
- Guarino A, Canani RB, Spagnuolo MI, Albano F, Di Benedetto L. Oral bacterial therapy reduces the duration of symptoms and of viral excretion in children with mild diarrhea. J Pediatr Gastroenterol Nutr. 1997; 25(5):516-9.
- Cetina-Sauri G, Busto GS. Therapeutic evaluation of Saccharomyces boulardii in children with acute diarrhea. Ann Ped. 1994;6:397-400.
 Hafeez A, Tariq P, Ali S, Kundi ZU, Khan A, Hassan M. The efficacy of
- Hafeez A, Tariq P, Ali S, Kundi ZU, Khan A, Hassan M. The efficacy of Saccharomyces boulardii in the treatment of acute watery diarrhea in children: a multicentre randomized controlled trial. J Coll Physicians Surg Pak. 2002;12:432-4.
- Kurugol Z, Koturoglu G. Effects of Saccharomyces boulardii in children with acute diarrhoea. Acta Paediatr. 2005;94(1):44-7.
 Billoo AG, Memon MA, Khaskheli SA, et al. Role of a probiotic (Saccha-
- Billoo AG, Memon MA, Khaskheli SA, et al. Role of a probiotic (Saccharomyces boulardii) in management and prevention of diarrhoea. World J Gastroenterol. 2006;12(28):4557-60.
- Ozkan TB, Sahin E, Erdemir G, Budak F. Effect of Saccharomyces boulardii in Children with Acute Gastroenteritis and Its relationship to the immune response. Journal of International Medical Research. 2007;35(2):201-12.
- Villarruel G, Rubio DM, Lopez F, et al. Saccharomyces boulardii in acute childhood diarrhoea: a randomized, placebo-controlled study. Acta Paediatr. 2007;96(4):538-41.
- Htwe K, Yee KS, Tin M, Vandenplas Y. Effect of Saccharomyces boulardii in the treatment of acute watery diarrhea in myanmar children: a randomized controlled study. Am J Trop Med Hyg. 2008;78(2): 214-6.
- Grandy G, Medina M, Soria R, Terán CG, Araya M. Probiotics in the treatment of acute rotavirus diarrhoea. A randomized, double-blind, controlled trial using two different probiotic preparations in Bolivian children. BMC Infectious Diseases. 2010;10:253.

Gaceta Médica de México. 2015;151

- Corrêa NB, Penna FJ, Lima FM, Nicoli JR, Filho LA. Treatment of acute diarrhea with Saccharomyces boulardii in infants. J Pediatr Gastroenterol Nutr. 2011;53(5):497-501.
- Dalgic N, Sancar M, Bayraktar B, Pullu M, Hasim O. Probiotic, zinc and lactose-free formula in children with rotavirus diarrhea: Are they effective? Pediatrics International. 2011;53(5):677-82.
- Shornikova AV, Casas IA, Isolauri E, Mykkänen H, Vesikari T. Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children. J Pediatr Gastroenterol Nutr. 1997;24(4):399-40.
- Shornikova AV, Casas IA, Mykkänen H, Salo E, Vesikari T. Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis. Pediatr Infect Dis J. 1997;16(12):1103-7.
- Rosenfeldt V, Michaelsen KF, Jakobsen M, et al. Effect of probiotic Lactobacillus strains in young children hospitalized with acute diarrhea. Pediatr Infect Dis J. 2002;21(5):411-6.
- Rosenfeldt V, Michaelsen KF, Jakobsen M, et al. Effect of probiotic Lactobacillus strains on acute diarrhea in a cohort of nonhospitalized children attending day-care centers. Pediatr Infect Dis J. 2002;21(5):417-9.
- Francavilla R, Lionetti E, Castellaneta S, et al. Randomised clinical trial: Lactobacillus reuteri DSM 17938 vs. placebo in children with acutediarrhoea--a double-blind study. Aliment Pharmacol Ther. 2012;36(4):363-9.
- Brooks WA, Santosham M, Roy SK, et al. Efficacy of zinc in young infants with acute watery diarrhea. American Journal of Clinical Nutrition. 2005;82(3):605-10.
- Fischer Walker CL, Bhutta ZA, Bhandari N, et al. Zinc supplementation for the treatment of diarrhea in infants in Pakistan, India and Ethiopia. J Pediatr Gastroenterol Nutr. 2006;43(3):357-63.
- Dutta P, Mitra U, Datta A, et al. Impact of zinc supplementation in malnourished children with acute watery diarrhoea. J Trop Pediatr. 2000;46(5):259-63.
- Fajolu IB, Emokpae A, Oduwole AO, Silva BO, Abidoye RO, Renner JK. Zinc supplementation in children with acute diarrhoea. Nig Q J Hosp Med. 2008;18(2):101-3.
- Patel A, Dibley MJ, Mamtani M, Badhoniya N, Kulkarni H. Zinc and copper supplementation in acute diarrhea in children: a double-blind randomized controlled trial. BMC Med. 2009;5(7):22.

- Sachdev HP, Mittal NK, Yadav HS. Oral zinc supplementation in persistent diarrhoea in infants. Ann Trop Paediatr. 1990;10(1):63-9.
- Pie'scik-Lech M, Shamir R, Guarino A, Szajewska H. Review article: the management of acute gastroenteritis in children. Aliment Pharmacol Ther. 2013;37(3):289-303.
- Guarino A, Dupont C, Gorelov AV, et al. The management of acute diarrhea in children in developed and developing areas: from evidence base to clinical practice. Expert Opin Pharmacother. 2012;13(1):17-26.
- World Health Organization. Diarrhoea. [Internet] Consultado el 7 de abril de 2013. Disponible en: http://www.who.int/topics/diarrhoea/en.
- National Collaborating Centre for Women's and Children's Health. Diarrhea and Vomiting Caused by Gastroenteritis: Diagnosis, Assessment and Management in Children Younger Than 5 Years. Londres: RCOG Press; 2009. [Internet] Consultado el 31 de marzo de 2012. Disponible en: http://www.nice.org.uk/nicemedia/pdf/CG84FullGuideline.pdf.
- Chow CM, Leung AK, Hon KL. Acute gastroenteritis: from guidelines to real life. Clin Exp Gastroenterol. 2010;3:97-112.
- Murphy C, Hahn S, Volmink J. Reduced osmolarity oral rehydration solution for treating cholera. Cochrane Database Syst Rev. 2004;4: CD003754.
- Rautenberg TA, Zerwes U, Foerster D, Aultman R. Evaluating the cost utility of racecadotril for the treatment of acute watery diarrhea in children: the RAWD model. Clinicoecon Outcomes Res. 2012;4:109-16.
- Szajewska H, Dziechciarz P, Mrukowicz J. Meta-analysis: Smectite in the treatment of acute infectious diarrhoea in children. Aliment Pharmacol Ther. 2006;23(2):217-27.
- Szajewska H, Skorka A, Ruszczynski M, Gieruszczak-Białek D. Meta-analysis: Lactobacillus GG for treating acute gastroenteritis in children – updated analysis of randomised controlled trials. Aliment Pharmacol Ther. 2013;38(5):467-76.
- Szajewska H, Skórka A, Dylag M. Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children. Aliment Pharmacol Ther. 2007;25(3):257-64.
- Lazzerini M, Ronfani L. Oral zinc for treating diarrhoea in children. Cochrane Database Syst Rev. 2013;1:CD005436.